Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients

Gény, Bernard; Mettauer, Bertrand; Muan, Berit; Bischoff, Pierre; Epailly, Éric; Piquard, François; Eisenmann, B; Haberey, P

doi:10.1016/0735-1097(93)90437-6

Cited by 66 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no interference with pulmonary gas exchange. These findings are in concordance with those of a similar patient study on Albunex, a contrast agent consisting of air filled albumin microspheres,6 as well as an experimental study in dogs using FS-069,7 which, like NC100100, is a second generation ultrasound contrast agent.…”

Section: Discussionsupporting

confidence: 90%

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease

Myreng¹,

Mølstad²,

Ytre-Arne³

et al. 1999

Heart

View full text Add to dashboard Cite

Objective-To evaluate the clinical and haemodynamic safety of NC100100, a new transpulmonary ultrasound contrast agent intended for vascular use. Design-Pulmonary artery pressures and gas exchange, left ventricular and systemic blood pressure and ECG were measured at baseline, after saline injection, and after each of two increasing doses of NC100100 injected intravenously. Patients-30 patients who were evaluated for suspected coronary artery disease. Results-No change was detected in any of the haemodynamic variables, or in haematological or clinical chemical parameters. Blood gases were unchanged, as were heart rhythm and arterial oxygen saturation. No serious adverse reactions were reported. Conclusions-NC100100 appeared to be haemodynamically inert and safe in patients with coronary artery disease. (Heart 1999;82:333-335)

show abstract

Section: Discussionsupporting

confidence: 90%

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease

Myreng¹,

Mølstad²,

Ytre-Arne³

et al. 1999

Heart

View full text Add to dashboard Cite

show abstract

“…HSA based formulations such as Abraxane [194,195] and Albunex [196] have shown good tolerability as evident from the clinical studies. So their efficacy of albumin formulations with minimum side effects is guaranteed.…”

Section: Albuminmentioning

confidence: 99%

Water Soluble Polymers for Pharmaceutical Applications

2011

View full text Add to dashboard Cite

Advances in polymer science have led to the development of novel drug delivery systems. Some polymers are obtained from natural resources and then chemically modified for various applications, while others are chemically synthesized and used. A large number of natural and synthetic polymers are available. In the present paper, only water soluble polymers are described. They have been explained in two categories (1) synthetic and (2) natural. Drug polymer conjugates, block copolymers, hydrogels and other water soluble drug polymer complexes have also been explained. The general properties and applications of different water soluble polymers in the formulation of different dosage forms, novel delivery systems and biomedical applications will be discussed.

show abstract

“…Albumin is an attractive macromolecular carrier that has been shown to be non-toxic, non-immunogenic, biodegradable to produce innocuous degradation products, and easy to purify [13]. It is thus a suitable candidate for nanoparticle preparation, as demonstrated by FDA-approved products such as Abraxane [14], [15] and Albunex [16], [17].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Cellular Uptake of Albumin-Based Lyophilisomes when Functionalized with Cell-Penetrating Peptide TAT in HeLa Cells

et al. 2014

View full text Add to dashboard Cite

Lyophilisomes are a novel class of biodegradable proteinaceous nano/micrometer capsules with potential use as drug delivery carrier. Cell-penetrating peptides (CPPs) including the TAT peptide have been successfully implemented for intracellular delivery of a broad variety of cargos including various nanoparticulate pharmaceutical carriers. In the present study, lyophilisomes were modified using CPPs in order to achieve enhanced cellular uptake. Lyophilisomes were prepared by a freezing, annealing, and lyophilization method and a cystein-elongated TAT peptide was conjugated to the lyophilisomes using a heterobifunctional linker. Fluorescent-activated cell sorting (FACS) was utilized to acquire a lyophilisome population with a particle diameter smaller than 1000 nm. Cultured HeLa, OVCAR-3, Caco-2 and SKOV-3 cells were exposed to unmodified lyophilisomes and TAT-conjugated lyophilisomes and examined with FACS. HeLa cells were investigated in more detail using a trypan blue quenching assay, confocal microscopy, and transmission electron microscopy. TAT-conjugation strongly increased binding and cellular uptake of lyophilisomes in a time-dependent manner in vitro, as assessed by FACS. These results were confirmed by confocal microscopy. Transmission electron microscopy indicated rapid cellular uptake of TAT-conjugated lyophilisomes via phagocytosis and/or macropinocytosis. In conclusion, TAT-peptides conjugated to albumin-based lyophilisomes are able to enhance cellular uptake of lyophilisomes in HeLa cells.

show abstract

Safety and efficacy of a new transpulmonary echo contrast agent in echocardiographic studies in patients

Cited by 66 publications

References 25 publications

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease

Safety of the transpulmonary ultrasound contrast agent NC100100: a clinical and haemodynamic evaluation in patients with suspected or proved coronary artery disease

Water Soluble Polymers for Pharmaceutical Applications

Enhanced Cellular Uptake of Albumin-Based Lyophilisomes when Functionalized with Cell-Penetrating Peptide TAT in HeLa Cells

Contact Info

Product

Resources

About